A Phase 1, Two-Stage, Dose-Escalation Study of BNC105P, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs BNC 105 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 27 Jun 2011 Status changed from active, no longer recruiting to completed.
- 23 Jun 2011 Results published in Clinical Cancer Research.
- 07 Jun 2010 Results reported at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Bionomics media release.